FindTrial
Sign In

Benefits of glutamine enriched feed over normal routine feed in traumatic brain injury patients:A double blinded RCT

A randomized double blind controlled trial to assess the benefits of glutamine enriched feed over normal routine feed in traumatic brain injury patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/02/004399
Enrollment
30
Registered
2014-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Head Injured

Interventions

Intervention1: glutamine enriched feed: glutamine 20 gm/day for 10days Control Intervention1: normal routine feed: normal routine feed that is being given for head injured patients in the selected hos

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Traumatic brain injured patients with GCS 5-12 Body mass index falling between 17-40 Age(18-60) Subjects who give consent to practice

Exclusion criteria

Exclusion criteria: Multiple organ system dysfunction Immune suppressive conditions(HIV,TB) Associated trauma such as pulmonary contusion, extremity fracture ,chest or intra-abdominal injuries Cancer or Taking chemotherapy or radiotherapy in last 6 months Chronic Obstructive Pulmonary Disease Renal failure Hepatic dysfunction Previous organ transplantation Pregnancy Indication of Total Parentral Nutrition Previously on antibiotics Chronic alcoholics and smokers

Design outcomes

Primary

MeasureTime frame
nutritional statusTimepoint: on day 3,5 and 10 after initiation of glutamine enriched feed—

Secondary

MeasureTime frame
infectious complicationsTimepoint: on day 3,5 and 10 after initiation of glutamine enriched feed—

Countries

India

Contacts

Public ContactREENA VT

AIIMS

pravigopi@gmail.com08130930287

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026